Ototoxicity

Cisplatin

Biology

Surgery

Clinical trial

Drug

Radiation therapy

Radiology

Bioinformatics

Pharmacotherapy

Internal medicine

Pharmacology

Schwannoma

Chemotherapy

Vestibular system

Oncology

Medicine

Acoustic neuroma

Audiology

Disease

Drug Design Development and Therapy

Abstract: Vestibular schwannomas (VSs, also known as acoustic neuromas) are benign intracranial tumors commonly managed with observation, surgery, and radiotherapy. There is currently no approved pharmacotherapy for VS patients, which is why we conducted a detailed search of relevant literature from PubMed and Web of Science to explore recent advances and experiences in drug therapy. VSs feature a long course of disease that requires treatment to have minimal long-term side effects. Conventional chemotherapeutic agents are characterized by neurotoxicity or ototoxicity, poor effect on slow-growing tumors, and may induce new mutations in patients who have lost tumor suppressor function, and therefore are unsuitable for treating VSs. Along with the well-investigated molecular pathophysiology of VS and the increasingly accessible technology such as drug repositioning platform, many molecular targeted inhibitors have been identified and shown certain therapeutic effects in preclinical experiments or clinical trials. Keywords: vestibular schwannomas, drug therapy, therapeutic targets, VEGFR inhibitor

A Review of Drug Therapy in Vestibular Schwannoma